Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA

BACKGROUND: Compared with basal-bolus insulin therapy (insulin glargine U100 plus insulin aspart), IDegLira has been shown to be associated with similar improvements in HbA1c, with superior weight loss and reduced hypoglycemia in patients with type 2 diabetes. The present analysis evaluated the cost...

Descripción completa

Detalles Bibliográficos
Autores principales: Billings, LK, Mocarski, M, Basse, A, Hunt, B, Valentine, WJ, Jodar, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432901/
https://www.ncbi.nlm.nih.gov/pubmed/30962697
http://dx.doi.org/10.2147/CEOR.S194719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432901/
https://www.ncbi.nlm.nih.gov/pubmed/30962697
http://dx.doi.org/10.2147/CEOR.S194719

Ejemplares similares